1-6 of 6
Nina Khoroshko
Close
Sort by
Journal Articles

The Role of Imatinib Plasma Level in the Achievment of Complete Cytogenetic Response (CCyR) in Chronic Myeloid Leukemia (CML) Therapy

Sergey Kutsev, MD, PhD, Oxana Oxenjuk, MD, Sergey Mordanov, MD, Yuri Shatokhin, MD, PhD, Tatiana Pospelova, MD, PhD, Nina Khoroshko, MD, PhD, Anna Turkina, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3789.
https://doi.org/10.1182/blood.V118.21.3789.3789
Published: 2011
Journal Articles

Results of Tyrosine Kinase Inhibitors (TKI) Therapy of Patients (Pts) with Chronic Myeloid Leukemia (CML) In Clinical Practice Analysed In the Frame of International Research Project EUTOS In Russian Federation

Anna G. Turkina, MD, PhD, Sergey Kulikov, Kudrat Abdulkadirov, Sergey Kutsev, MD, PhD, Anatoly Golenkov, MD, Valentina Ivanova, Tatiana Pospelova, MD, PhD, Tatiana Konstantinova, Olga Lazareva, PhD, Nina Khoroshko, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 4447.
https://doi.org/10.1182/blood.V118.21.4447.4447
Published: 2011
Journal Articles

Clinical Significance of Additional Chromosomal Abnormalities In Ph-Positive and Ph-Negative Cells In Patients with Chronic Myeloid Leukemia Treated by Tyrosine Kinase Inhibitors

Anna G. Turkina, MD, PhD, Olga Vinogradova, PhD, Alexandra Vorontsova, PhD, Ekaterina Chelysheva, PhD, Olga Lazareva, PhD, Galina Gusarova, PhD, Elena Aseeva, PhD, Nina Khoroshko, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1683.
https://doi.org/10.1182/blood.V118.21.1683.1683
Published: 2011
Journal Articles

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Clinical Trials & Observations
Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, Pedro Dorlhiac-Llacer, Ricardo Pasquini, John DiPersio, Martin C. Müller, Jerald P. Radich, H. Jean Khoury, Nina Khoroshko, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman
Journal: Blood
Blood (2009) 113 (25): 6322–6329.
https://doi.org/10.1182/blood-2008-11-186817
Published: 2009
Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, PhD, Pedro Dorlhiac-Llacer, Ricardo Pasquini, Nina Khoroshko, John F. DiPersio, MD, PhD, Martin C Müller, MD, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman, MD
Journal: Blood
Blood (2008) 112 (11): 3224.
https://doi.org/10.1182/blood.V112.11.3224.3224
Published: 2008
Journal Articles

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Clinical Trials & Observations
Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Holowiecki, Saengsuree Jootar, Tadeusz Robak, Nina Khoroshko, Tamas Masszi, Aleksander Skotnicki, Andrzej Hellmann, Andrey Zaritsky, Anatoly Golenkov, Jerald Radich, Timothy Hughes, Athena Countouriotis, Neil Shah
Journal: Blood
Blood (2007) 109 (12): 5143–5150.
https://doi.org/10.1182/blood-2006-11-056028
Published: 2007